Keros up after acquiring major investors' shares at premium; unveils $194 million buyback plan

Keros Therapeutics

15/10/2025 14:03

** Shares of drug developer Keros Therapeutics KROS.O rise 1.8% to $15.36 in early trade

** Co to repurchase all shares held by ADAR1 Capital Management and Pontifax Venture Capital for $181 million at $17.75 per share

** Co plans tender offer to repurchase up to $194 mln more shares at $17.75 each

** Will return 25% of Takeda license proceeds to shareholders by end-2028 – KROS

** Board members of Keros Therapeutics, Ran Nussbaum and Tomer Kariv resign following deal - KROS

** Co says buyback part of $375 mln capital return program; funded via cash reserves

** Mid-stage trial of KER-065 trial in muscle-wasting disease DMD to begin in first quarter of 2026 – KROS

** Up to last close, stock down ~5% YTD

(Reporting by Sahil Pandey)

((Sahil.Pandey@thomsonreuters.com))